Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

@article{Eloseily2019BenefitOA,
  title={Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis},
  author={Esraa M. Eloseily and Peter Weiser and Courtney B Crayne and Hilary Haines and Melissa L. Mannion and Matthew L. Stoll and Timothy Beukelman and T. Prescott Atkinson and Randy Q. Cron},
  journal={Arthritis \& Rheumatology},
  year={2019},
  volume={72}
}
To assess the benefit of the recombinant human interleukin‐1 receptor antagonist anakinra in treating pediatric patients with secondary hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) associated with rheumatic and nonrheumatic conditions. 
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis
TLDR
Anakinra, a recombinant interleukin‐1 receptor antagonist, has been reported to treat macrophage activation syndrome (MAS), rheumatic sHLH, and the experience with anakinra to treat patients with nonrheumatic secondary HLH is reported.
Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children
TLDR
Interleukin‐1 (IL‐1) receptor blockade with anakinra can be effective in the management of sHLH/MAS and IV dosing is advantageous where time‐critical intervention is vital and where SC oedema and/or hypoperfusion limits absorption.
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin‐1 receptor antagonist) infusions in
Management of Other Toxicities
TLDR
There have been increasing reports of sHLH/MAS occurrence following CAR-T cell therapy, but its differentiation from cytokine release syndrome (CRS) is often difficult.
Anakinra Therapy for Hemophagocytic Lymphohistiocytosis
TLDR
There is insufficient information to draw reliable conclusions regarding the clinical effectiveness of anakinra compared to standard treatments for patients diagnosed with HLH and no evidence on the safety or cost-effectiveness of the drug compared to current standard treatments or to placebo was identified.
Macrophage Activation Syndrome in Children: Diagnosis and Management
TLDR
This review outlines the key clinical and laboratory features and management of macrophage activation syndrome.
Comment on: The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis
TLDR
Three patients treated for HLH with concomitant SoJIA diagnosis at Cook Children’s Medical Center between 2014 and 2019 are described below in order to examine the role of immunomodulators in their clinical course and outcome.
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Hemophagocytic Lymphohistiocytosis for the Internist and Other Primary Care Providers
TLDR
The essentials that an internist and other primary care providers managing adult HLH patients should know are reviewed, requiring early initiation of immunosuppressive treatment.
Treatment of hemophagocytic lymphohistiocytosis in the era of new biologics
  • K. McClain
  • Medicine, Biology
    Pediatric blood & cancer
  • 2020
TLDR
This article will present a brief overview of several biologic treatments that target different elements of the HLH pathophysiology, driven by a hyperactive immune response fromcytotoxic T cells trying to eliminate target cells by elaborating a number of cytokines.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party
We analyzed a nationwide registry of pediatric patients with hemophagocytic lymphohistiocytosis (HLH) in Korea to assess the clinical and genetic features and treatment outcomes in pediatric HLH.
Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
Because it has no unique clinical, biologic, or histologic features, reactive hemophagocytic syndrome may be difficult to distinguish from other diseases such as severe sepsis or hematologic
Macrophage activation syndrome.
TLDR
This study presents new findings in hemophagocytic lymphohistiocytosis, a disease that is clinically simulating systemic inflammatory disorders.
Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
TLDR
To compare the capacity of the 2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis with the capacity for systemic juvenile idiopathic arthritis–associated macrophage activation syndrome to discriminate MAS complicating systemic JIA, two potentially confusable conditions are compared.
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients
To describe the clinical, laboratory, and histopathologic features, current treatment, and outcome of patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic
Whole‐Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic Lymphohistiocytosis
TLDR
This study undertook this study to test the hypothesis that MAS predisposition in systemic JIA could be attributed to rare gene sequence variants affecting the cytotolytic pathway.
Persistent defective membrane trafficking in epithelial cells of patients with familial hemophagocytic lymphohistiocytosis type 5 due to STXBP2/MUNC18‐2 mutations
TLDR
Clinical findings suggest an impaired expression and function of STXBP2 in cells other than cytotoxic lymphocytes in patients with familial hemophagocytic lymphohistiocytosis.
The Immunology of Macrophage Activation Syndrome
TLDR
In addition to broadly immunosuppressive therapies, novel cytokine targeted treatments are being explored to dampen the overly active immune response that is responsible for much of the pathology seen in MAS.
Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome – Successful use of PET- CT and Anakinra in its diagnosis and treatment
TLDR
The present case illustrates the difficulties in diagnosing MAS when multiple bone marrow biopsies fail to show hemophagocytosis and describes the important role of Anakinra in treating refractory cases of MAS.
The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis
TLDR
The purpose of this study was to quantify the number of HPC in the initial BMA in patients diagnosed with HLH at the authors' institution.
...
1
2
3
4
5
...